The causal role of FMO3 is supported by interventional studies, whether TMAO itself is an independent pathogenic driver or a biomarker in human obesity requires further clarification (Caradonna et al., 2025). Here, FMO3 is linked to obesity due to melanocortin 4 receptor deficiency.